Compare XEL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XEL | ONC |
|---|---|---|
| Founded | 1909 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | 12000 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9B | 40.6B |
| IPO Year | 2003 | 2015 |
| Metric | XEL | ONC |
|---|---|---|
| Price | $77.44 | $376.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $89.00 | ★ $385.10 |
| AVG Volume (30 Days) | ★ 4.7M | 356.8K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | ★ 1.82 | 0.31 |
| Revenue | ★ $11,537,000,000.00 | $238,387,000.00 |
| Revenue This Year | $9.77 | $723.76 |
| Revenue Next Year | $8.32 | $15.04 |
| P/E Ratio | ★ $42.49 | $1,199.94 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $71.29 | $253.95 |
| 52 Week High | $84.23 | $385.22 |
| Indicator | XEL | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 69.42 |
| Support Level | $77.00 | $325.47 |
| Resistance Level | $82.05 | $385.22 |
| Average True Range (ATR) | 1.39 | 7.78 |
| MACD | -0.07 | 1.00 |
| Stochastic Oscillator | 27.48 | 89.03 |
Xcel Energy manages utilities serving 3.9 million electric customers and 2.2 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy suppliers in the US, with more than half of its electricity sales coming from carbon-free energy.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.